UroGen Pharma Ltd.

UroGen Pharma Ltd.

URGNNYSE / NASDAQHealthcareSmall cap

$27.65-$4.08 (-12.9%)

Last close · Data as of Nov 20, 2026

Market cap
$1.3B
P/E
-8.8x
EV / EBITDA
-10.0x
Revenue
$109.8M
Net margin
-139.8%
ROCE
-81.1%

+11.3% over the last year

UroGen Pharma Ltd. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-21.0%
3M
-40.9%
6M
-8.5%
1Y
+11.3%
5Y
+129.3%

52-week range

Day change -$4.08 (-12.9%) from $32 to $28 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in URGN, bought on each weekday since 2021.

News & filings

What UroGen Pharma filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Current assets are 4.01 times current liabilities.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

Read moreShow less

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Sector
Healthcare
Shares outstanding
48.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.3B
P/E
-8.8x
P/B
-12.7x
EV / EBITDA
-10.0x
EV / Sales
12.4x
P/S
12.2x
52-week high
$50.29
52-week low
$17.00

Profitability

Operating margin
-113.7%
Net margin
-139.8%
EBITDA margin
-123.6%
ROE
145.5%
ROCE
-81.1%
ROA
-76.6%
Asset turnover
0.55

Growth

Revenue
$109.8M
Revenue growth, 1Y
21.4%
Revenue CAGR, 3Y
19.5%
Net profit growth, 1Y
21.0%
Free cash flow
-$162.7M

Solvency

Current ratio
4.01
Debt / Equity
-1.22
Debt / Assets
0.64
CFO / Net profit
1.06
Cash / Market cap
8.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$109.8M
Cost of revenue$12.4M
Gross profit$97.3M
Operating expenses$222.2M
Research and development$67.1M
Selling, general and administrative$155.1M
Operating income-$124.9M
Interest and other-$28.6M
Pretax income-$153.4M
Tax and other$70.0k
Net income-$153.5M

Revenue and net profit

Revenue grew 21.4% in FY2025; net profit is the dashed line.

UroGen Pharma Ltd. revenue and net profit by fiscal year
UroGen Pharma Ltd. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$64.4M-$109.8M
FY2023$82.7M-$102.2M
FY2024$90.4M-$126.9M
FY2025$109.8M-$153.5M

Cash flows

FY2025: -$162.4M from operations, -$162.7M free after investment (dashed).

UroGen Pharma Ltd. operating and free cash flow by fiscal year
UroGen Pharma Ltd. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$87.6M-$87.8M
FY2023-$76.4M-$76.6M
FY2024-$96.8M-$97.1M
FY2025-$162.4M-$162.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$109.8M+21.4%1Y
EBITDA
-$135.7M
Net profit
-$153.5M
Cash from operations
-$162.4M
Free cash flow
-$162.7M
Revenue CAGR, 3Y
19.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$109.8M-$135.7M-$153.5M-$162.7M145.5%+21.4%+21.0%

Monthly returns

Month-by-month returns of URGN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$200.5M
Liabilities$305.9M
Equity-$105.5M
Paid-in capital$854.1M
Retained earnings-$959.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; URGN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. UroGen Pharma Ltd. (this company)12.4x

Not shown (no positive earnings and no EV / Sales): MapLight Therapeutics, Inc., Bicara Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
UroGen Pharma Ltd.URGNthis company$1.3B-8.8x-12.7x145.5%-10.0x
MapLight Therapeutics, Inc.MPLT$1.4B—3.0x-35.2%—
Butterfly Network, Inc.BFLY$1.4B—6.9x-39.3%—
Bicara Therapeutics Inc.BCAX$1.3B-9.7x3.3x-34.4%-8.0x
Inhibrx Biosciences, Inc.INBX$1.3B-9.6x167.5x-1752.2%-10.5x
Ardelyx, Inc.ARDX$1.3B-21.7x8.0x-36.9%-50.5x
Tandem Diabetes Care, Inc.TNDM$1.3B-6.5x8.6x-131.9%-9.6x
AdaptHealth Corp.AHCO$1.3B-18.7x0.9x-4.7%6.6x
BioLife Solutions, Inc.BLFS$1.3B-288.0x3.6x-1.2%-109.8x
Peer median—-14.2x5.2x-36.0%-10.0x

Year-to-date ROI

URGN since 1 January, against earlier years.

Historical volatility

URGN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

UroGen Pharma Ltd. operating margin by fiscal year
UroGen Pharma Ltd. operating margin by fiscal year
DateOperating margin
FY2022-122.8%
FY2023-79.2%
FY2024-107.1%
FY2025-113.7%
LineFY2025
Cost of revenueCost Of Revenue$12.4M
Gross profitGross Profit$97.3M
Operating expensesOperating Expense$222.2M
Research and developmentResearch And Development$67.1M
Selling, general and administrativeSelling General And Administration$155.1M
Total expensesTotal Expenses$234.7M
Pretax incomePretax Income-$153.4M

Learn while you research

Academy chapters picked for UroGen Pharma Ltd. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing21% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →